TB R&D Weekly Update: Podcast Interview with Dr. Tawanda Gumbo

Dr. Tawanda Gumbo

Listen to Tawanda Gumbo Podcast

Summary: Dr. Tawanda Gumbo, an associate professor at the The University of Texas Southwestern Medical Center, recently published a paper in the Journal of Infectious Diseases entitled “Multidrug-resistant tuberculosis not due to noncompliance but to between-patient pharmacokinetic variability.” The paper puts forth evidence that nonadherence may not be the prime reason for the emergence of drug resistance in TB but instead that the differences or fluctuations in the way patients absorb, metabolize and retain the drug in their bodies contributes to the emergence of resistance to TB drugs. In this interview, we discuss the recently published paper, his research interests and background, the recent debate on the role of efflux pumps in drug tolerance and his research to optimize TB drugs.

Dr. Gumbo’s research is focused on advanced pharmacometrics, antimicrobial pharmacokinetic-pharmacodynamics and pharmacogenetics, clinical trial simulations using Monte Carlo Methods, individualized Bayesian dose optimization, as well as, the molecular and cellular pharmacology of antituberculosis and other antimycobacterial agents.

Additional TB R&D News:

Recent exchange on the topic of Moxifloxacin use:

Rational use of moxifloxacin for tuberculosis treatment

Moxifloxacin for tuberculosis (Mendel & Springsklee)

Moxifloxacin for tuberculosis (Singh, et al.)

Moxifloxacin for tuberculosis — Authors’ reply

Other news links:

SymptomsofTuberculosis.Net Launches to Address Rising Concerns Over Tuberculosis and Symptoms of Tuberculosis

Biomedical company sets up in Memphis

Combating TB, the right way

Polio eradication has a lesson for TB control

More News
19 Mar 2024
For World TB Day 2024, the WGND is spotlighting a monumental achievement in TB drug research and development: the Global TB Drug Pipeline has never been bigger than it is today. The number of drug candidates being clinically evaluated for use in the treatment of adult pulmonary TB has surpassed...
3 Aug 2023
The Working Group on New TB Drugs, in collaboration with the New Diagnostics Working Group, Working Group on New Vaccines, FIND, IAVI, and TB Alliance, is co-hosting a New Tools Summit at the Marriot Champs Elysée Hotel in Paris, France on Tuesday, 14 November 2023. The WGND Annual Meeting will be...
23 Aug 2022
The PAN-TB collaboration announced initial plans for a Phase 2 clinical trial evaluating two novel drug regimens to treat Tuberculosis. Sponsored by the Bill and Melinda Gates Foundation, the PAN-TB, or “Project to Accelerate New Treatments for Tuberculosis”, collaboration brings together non-...